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Abstract
Background: Transcriptome sequencing of brain samples provides detailed enrichment analysis of differential
expression and genetic interactions for evaluation of mitochondrial and coagulation function of schizophrenia. It is
implicated that schizophrenia genetic and protein interactions may give rise to biological dysfunction of energy
metabolism and hemostasis. These findings may explain the biological mechanisms responsible for negative and
withdraw symptoms of schizophrenia and antipsychotic-induced venous thromboembolism.
We conducted a comparison of schizophrenic candidate genes from literature reviews and constructed the
schizophrenia-mediator network (SCZMN) which consists of schizophrenic candidate genes and associated
mediator genes by applying differential expression analysis to BA22 RNA-Seq brain data. The network was searched
against pathway databases such as PID, Reactome, HumanCyc, and Cell-Map. The candidate complexes were
identified by MCL clustering using CORUM for potential pathogenesis of schizophrenia.
Results: Published BA22 RNA-Seq brain data of 9 schizophrenic patients and 9 controls samples were analyzed. The
differentially expressed genes in the BA22 brain samples of schizophrenia are proposed as schizophrenia candidate
marker genes (SCZCGs). The genetic interactions between mitochondrial genes and many under-expressed SCZCGs
indicate the genetic predisposition of mitochondria dysfunction in schizophrenia. The biological functions of SCZCGs, as
listed in the Pathway Interaction Database (PID), indicate that these genes have roles in DNA binding transcription
factor, signal and cancer-related pathways, coagulation and cell cycle regulation and differentiation pathways.
In the query-query protein-protein interaction (QQPPI) network of SCZCGs, TP53, PRKACA, STAT3 and SP1 were
identified as the central “hub” genes. Mitochondrial function was modulated by dopamine inhibition of respiratory
complex I activity. The genetic interaction between mitochondria function and schizophrenia may be revealed by
DRD2 linked to NDUFS7 through protein-protein interactions of FLNA and ARRB2.
The biological mechanism of signaling pathway of coagulation cascade was illustrated by the PPI network of the
SCZCGs and the coagulation-associated genes. The relationship between antipsychotic target genes (DRD2/3 and
HTR2A) and coagulation factor genes (F3, F7 and F10) appeared to cascade the following hemostatic process
implicating the bottleneck of coagulation genetic network by the bridging of actin-binding protein (FLNA).
Conclusions: It is implicated that the energy metabolism and hemostatic process have important roles in the
pathogenesis for schizophrenia. The cross-talk of genetic interaction by these co-expressed genes and reached
candidate genes may address the key network in disease pathology. The accuracy of candidate genes evaluated from
different quantification tools could be improved by crosstalk analysis of overlapping genes in genetic networks.
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Background
The etiology of schizophrenia has been gaining more
focus in recent brain research. One of the most intri-
guing areas of schizophrenia research is the identifica-
tion of candidate genes from different postmortem
cortical regions associated with positive and negative
symptoms for the pathophysiology of schizophrenia.
The neurodevelopmental studies of schizophrenia have
used postmortem superior temporal gyrus (STG/BA22)
tissue samples which are responsible for cognition and
memory. Next generation sequencing (NGS) accelerates
biological research in disease pathology such as geno-
mics, transcriptomics, gene expression analysis[1]. Schi-
zophrenia is a complex neurodevelopmental disorder.
The vulnerability basis of schizophrenia demonstrates
the genetic deficit of the complex heritability. The use
of RNA-Seq technology provides a more complete data-
set for transcriptome analysis than microarray technol-
ogy. Six public human brain RNA-Seq datasets, as listed
in Table 1, are currently available from the sequence
read archive (SRA).
Accumulating evidence suggests that mitochondria
dysfunction is one of the pathological mechanisms for
schizophrenia. Genetic variations in mitochondrial
DNA polymorphism and antipsychotic-induced weight
gain are associated with schizophrenic subjects[2]. The
ATP level was decreased in the left temporal in schizo-
phrenic patients[3] and mitochondrial DNA common
deletion in brain samples and polymorphisms are asso-
ciated with schizophrenic patients[4,5], suggesting that
the alteration of mitochondria and dysregulation of
energy metabolism may contribute to implication of
schizophrenia[6,7].
Venous thromboembolic events have been associated
with psychosis in unmedicated schizophrenic patients
[8]. Evidence indicates that abnormal tissue plasminogen
activator (tPA) activity is an important predisposing fac-
tor for schizophrenia[9]. Moreover, chronic anticoagula-
tion therapy is associated with remission of psychotic
symptoms, which suggest that imbalance of tPA levels
in the brain may affect the stabilization of psychotic
symptoms[10]. Proteomic study provided evidence that
serum abnormalities in schizophrenic patients involved
in phosphorylation of proteins in coagulation pathways
[11]. It has been suggested that drug-induced sedation,
obesity and enhanced platelet aggregation result in
increased activity in the coagulation system[12-14].
The studies by Huang et al.[15], Wu et al.[16] and
Sellmann et al.[17] used human postmortem brain tissue
samples for schizophrenia research. The previous post-
mortem brain studies in schizophrenia by Huang et al.
(2013) contains 19 control and 23 schizophrenia micro-
array samples of BA22 brain tissue[18]. Sellmann et al.
(2013) used 10 schizophrenia patients and 10 controls
in their microarray study. KJ Brennand et al.(2011) col-
lects 4 samples from schizophrenia patients and 4 con-
trols to derive the human induced pluripotent stem
cells. There are few RNA-Seq datasets available in post-
mortem brain samples mostly because of its high cost.
RNA-Seq is a high-throughput sequencing technique as
an alternative to microarray for genotyping, which its
sequencing data are highly replicable with little technical
variation, and it enables more accurate identification of
differentially expressed genes, alternative splice variants
and novel transcripts[19]. The SRA database contained
36 public NGS biosamples associated with schizophre-
nia. Therefore, the 9 schizophrenic samples and 9 con-
trols collected by Wu et al. used in this study are of
reasonable sample size for transcriptome analysis. The
human brain area STG/BA22 is believed to be asso-
ciated with speech and language, known as Wernicke’s
area, and responsible for many positive symptoms and
cognitive dysfunction involving auditory processing and
social cognition in schizophrenia. Wu et al. revealed
three functional clusters highly relevant to schizophrenia
in STG/BA22 with the use of RNA-Seq[16]. Using sys-
tems biology and bioinformatic analysis tools, the
pathology and disease mechanisms for schizophrenia
Table 1 Publicly available human brain RNA-Seq datasets on the SRA database.
Tissue location Sample
size
Disease type Author Organization Publication
date
temporal cortex: 6 3 Autism vs 3 Control Xinchen Wang University of Toronto 12-Jul-11
human reference brain
RNA
16 - Daniel Ramsköld Karolinska Institute 16-Jul-12
caudate nucleus 5 - Genevieve
Konopka
UT Southwestern Medical Center 9-Nov-11
frontal pole 6 - Genevieve
Konopka
UT Southwestern Medical Center 9-Nov-11
hippocampus 6 - Genevieve
Konopka
UT Southwestern Medical Center 9-Nov-11
Superior temporal gyrus 18 9 schizophrenia vs 9
control
Jing Qin Wu The Ramaciotti Centre, NSW,
Australia
9-May-12
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were gradually resolved to discover new biological path-
ways, targets and new treatment strategy. Sun J. et al.
(2010) reported schizophrenic networks and pathways
[20]. Disease networks were drawn for this complex dis-
ease[21], and the relationship between schizophrenia
and cancer has also been investigated[15].
In Phenopedia, the most reported schizophrenia-
related gene was COMT, which was supported by 278
publications; whereas DRD2 and BDNF are supported
by 139 and 116 publications respectively. ATF3 is con-
sistently under-expressed and appears in four different
databases in both RNA-Seq and microarray analyzed
brain samples, further evidence suggest that the ATF3
associated TREM-1 gene has significantly increased
expression in monocytes of schizophrenia patients[22].
The association of schizophrenia and the under-expres-
sion of the FOXN3 gene has been reported[23,24].
A complementary research to evaluate the deficit in
schizophrenia requires GWAS analysis of candidate
genes, SNP changes of specific gene, clinical quantitative
endophenotypes, genetic network and protein function-
ality from microarray, and NGS data of peripheral blood
and postmortem brain samples. This study explores the
SCZCGs consistently found in different tissue-specific
datasets, focusing on the genotypes of hemostasis and
energy metabolism in schizophrenia. To illustrate the
pathology of schizophrenia, differentially expressed can-
didate genes were constructed into protein-protein
interaction (PPI) networks. Relevant pathways and pro-
tein complexes were analyzed to discover novel cellular
function or disease mechanism by systems biology in
schizophrenia. Moreover, the co-expressed SCZGCs
from different schizophrenic datasets were used to
demonstrate the relationships of coagulation and mito-
chondrial function in schizophrenia.
Methods
Selection of differential expression genes by quantifying
transcript abundances of postmortem brain tissue in
schizophrenia
The raw reads datasets (SRA: ERP001304, BioProject:
PRJEB2939) were downloaded from the NCBI SRA data-
base. In ERP001304[16], total RNA was extracted from
postmortem BA22 STG tissue from 9 schizophrenic
patients and 9 matched controls sourced from the NSW
Tissue Resource Center, the University of Sydney, Austra-
lia. Other publicly available human brain RNA-Seq data-
sets in NCBI SRA database are listed in Additional file 1.
We aligned the FASTQ data of ERP001304 to the
reference human transcriptome using Bowtie 1 and
sorted using SAMtools[25]. In order to quantify tran-
script abundances, RSEM[26] was used to normalize
RNA-Seq data for each sample into transcripts per
million (TPM). The significant differentially expressed
transcripts with over- or under-expressed genes in the
BA22 STG brain specimen were selected by using the
Student’s t-test between the schizophrenia and control
samples. The corresponding t-test of each gene with a
p-value less than 0.05 was defined as candidate genes
for schizophrenia (SCZCGs).
Analysis flow of NGS datasets related with postmortem
brain tissue in schizophrenia
A key challenge in transcript quantification from RNA-
Seq data is the handling of reads that map to multiple
genes or isoforms. We used tools such as Bowtie 1[27]
and Tophat[28] to align the reads. We also used quanti-
fication tools such as Cufflinks[29] and RSEM[26] to
estimate the abundance and differential expression of
transcripts. Different quantification measures used in
transcriptome analysis could result in different sets of
candidate genes[30]. RSEM computes the maximum
likelihood abundance using the Expectation-Maximiza-
tion (EM) algorithm for optimal distribution of multiple
hit reads[31]. The primary output of RSEM is a measure
of abundance in terms of transcripts per million (TPM).
The TPM measure is preferred over the RPKM and
FPKM measures because it is independent of the mean
expressed transcript length and is thus more comparable
across samples[30]. The analytical process for the dis-
covery of candidate genes, protein-protein interactions
and corresponding pathways are illustrated in Figure 1.
Student’s t-test was performed to identify significant dif-
ferentially expressed genes as SCZCGs.
To illustrate the pathology of schizophrenia, differen-
tially expressed candidate genes, protein-protein interac-
tions (PPIs), related pathways and protein complexes
were analyzed to discover novel cellular functions or
disease mechanism by systemic biology in schizophrenia
[15,20]. The PPIs were collected from BIND[32], HPRD
[33] and BioGrid[34] to construct the schizophrenic PPI
network.
Analysis of schizophrenic mediator network
With the SCZCGs, we constructed the schizophrenic
candidate genes and mediator network (SCZMN) to
illustrate the PPI network of SCZCGs with mediators.
Mediators were defined as protein nodes which interact
with SCZCGs and have a degree greater than one (i.e.
have interaction with proteins in addition to the
SCZCGs).
The mediator genes could manifest to the characteris-
tic of SCZMN in disease pathways. The SCZMN was
searched against DAVID[35], MCL[36] and CORUM
[37] for biological functions, subnetwork clustering and
potential protein complexes.
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Schizophrenic network analysis with fold-change
subnetwork clustering
By applying the Markov cluster algorithm (MCL)[36,38],
the combination of corresponding modulation from
each node was calculated. Each node in SCZMN was
weighted by fold change (FC) which was calculated by
dividing the schizophrenic expression mean (SM) by the
control expression mean (CM). To account for the co-
regulatory relationship between two nodes, FC of adja-
cent nodes were multiplied to represent the edge rela-
tionship of two neighbouring nodes and used as the
MCL input. The co-regulation of subnetworks in schizo-
phrenia was analyzed by MCL to explore the biological
components and processes in schizophrenia.
Analysis of regulatory relationship between pathways
involving schizophrenic candidate genes
Pathway analysis is the building process of identifying
protein interactions, associated annotation and domain
knowledgebase[39]. The pathway enrichment analysis
was performed with PID[40], Reactome[41], Cell-Map
[42] and HumanCyc[43] databases to obtain the poten-
tial pathways for the pathophysiology of schizophrenia.
For obtaining potentially involved pathways in schizo-
phrenia, the pathway enrichment analysis of the signifi-
cant differentially expressed genes are prioritized and
the significance of corresponding pathways is ranked by
p-value with FDR less than 0.05 with the Benjamini-
Hochberg procedure using fdrtool[44].
Results
Exploration of schizophrenia candidate genes from
different literature datasets
The significantly differential expressed genes were
selected based on the curated database of literature
reviews, laboratory reports, microarray differential
expression analysis, generic risk prediction and RNA-
Seq data analysis. Several novel candidate genes and
potential pathways were associated to the susceptibility
mechanism of schizophrenia. The candidate genes
reported by SZGene[45], Huang et al.(2013)[15], Sell-
mann et al.(2013)[17], Ayalew M et al.(2012)[46], Wu et
al.(2012)[16] and SCZCGs were compared and revealed
high inconsistency of putative genes and pathways,
results are listed in Additional file 2. NCBI ClinVar[47]
provides pathogenic, protective and risk factors asso-
ciated with schizophrenia, which was used to investigate
the relationship between clinical manifestation and can-
didate genes.
The phenomenon of inconsistency of reported schizo-
phrenic candidate genes are common between 9 different
studies. Only 15 schizophrenic candidate genes with count
numbers above 4 have large numbers of publications. The
less candidate genes been mentioned in studies (counts),
the less publication reports support. There are 3688 schi-
zophrenic candidate genes mention only once in the 9 stu-
dies. 620 of them have been reported in literature
including NRG1 which has 107 publication reports mostly
in GWAS and animal study but not been reported in
human post-mortem studies. Even the candidate genes in
human induced pluripotent stem cell (HiPSC) study are
greatly different from human brain studies, the inconsis-
tent result may result from different tissue samples, mea-
surement techniques, quantification analysis tools and
experimental condition. It is implicated the characteristic
of heterogeneity and diverse transcriptome expression in
schizophrenia.
Many identified cellular functions and proteins as well
as candidate genes are involved in schizophrenia. There
are total 3505 schizophrenic candidate genes reported in
literature. The studies of Huang et al., Wu et al. and Sell-
mann et al. used human postmortem brain tissue sample,
there are also studies using other tissue-specific speci-
mens including human blood and cell culture experi-
ments from schizophrenic patients. The DISC1 and
BDNF genes are the top most reported schizophrenic
candidate genes. The second most reported candidate
Figure 1 The analytical flow discovering candidate genes and
pathways. By analysis of NGS data from BA22 STG sample, the
significant differential genes were screened by Bowtie 1 and RSEM
to construct the QQPPI network for schizophrenia. The potential
complexes or pathways which were searched against pathway and
protein complex databases such as NCI-PID, Reactome, Cell-Map,
HumanCyc and CORUM are obtained by MCL cluster with the
corresponding bioinformatic tools. The right part shows the
corresponding analytical tools for the analysis of candidate PPI
subnetworks and pathways.
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genes are MTHFR, GAD1, COMT, ATF3, and APOE,
which are reported in at least four literature reviews. The
results reported by different databases are highly incon-
sistent with different papers reporting mostly different
candidate genes.
Schizophrenic candidate genes by different alignment
and quantification tools
A key challenge in transcript quantification from RNA-
Seq data is the handling of reads that map to multiple
genes or isoforms. RSEM computes maximum likelihood
abundance estimates using the Expectation-Maximiza-
tion (EM) algorithm for its statistical model[31]. The
primary output of RSEM is a measure of abundance in
terms of transcripts per million (TPM). The TPM mea-
sure is preferred over the popular RPKM and FPKM
measures because it is independent of the mean
expressed transcript length and is thus more comparable
across samples[30].
Wu et al. used the TopHat and Cufflinks pipeline for
alignment and tests for differential expression. In this
study, the same RNA-Seq data was analyzed by Bowtie
1 for alignment and RSEM for transcript quantification
to obtain candidate genes (Additional file 3). There are
722, 511 and 961 candidate genes reported by Wu et al.,
SCZCGs and SZGene, respectively. Only the genes
FGF1 and SPARCL1 appear in all three datasets. 62
identical candidate genes appear in both SZGene and
Wu et al. 31 identical candidate genes exist in both
SZGene and SCZCGs. There are 30 candidate genes in
both Wu et al. and SCZCGs. There are total 369 under-
expressed genes and 353 over-expressed candidate genes
in schizophrenia from Wu et al. There are 23 under-
expressed and 6 over-expressed candidate genes
(S100A13, RPS14, RPRM, NUDT3, MAP4K4 and FGF1)
identical to SCZCGs. It was implicated that different
analytical alignment and quantification tools may result
in partially similar but complementary candidate gene
groups. Only 2 genes appear in all three datasets: FGF1
and SPARCL1. SNPs in FGF1 were reported to be asso-
ciated with the risk of developing schizophrenia[48]. Wu
et al. reported 11 under-expressed genes and 2 over-
expressed candidate genes in the mitochondria. How-
ever, there is only one candidate gene (NDUFB11)
involved in mitochondrial function in SCZCGs.
In Figure 2, Wu at al. reported 722 candidate genes
using the Tophat and Cufflinks pipeline. However, using
the same RNA-Seq data with Bowtie 1 and RSEM
resulted in 511 candidate genes (SCZCGs). These results
show that the use of different alignment and quantifica-
tion tools may result in a completely different set of
candidate genes with little consistency, and even more
so when compared with the 781 candidate genes in
SZGene. 62 genes appear in both Wu el al. and SZGene,
31 genes appear in both SCZCGs and SZGene. Total 91
genes were selected from Wu et al. and SCZCGs which
were matched in SZGene. These matched genes may
indicate the more robust candidate genes for schizo-
phrenia with publication supports. However, there are
28 overlapped genes appear in both candidate genes of
SCZCGs and Wu et al. but not in SZGene, which they
may be implicated the potential candidate genes for
schizophrenia and need validation in the future study.
The few overlapped candidate genes selected from dif-
ferent quantification tools and measurement conditions
may reflect the heterogeneity of complex disease such as
schizophrenia. It may implicate the importance of med-
iator genes as the key role of disease susceptibility
which is more conserved in the candidate genetic net-
work of schizophrenia[15]. Similarly, the inconsistency
of schizophrenic candidate genes was also showed by
Wu et al. and Huang et al. using the same RNA-Seq
datasets of post-mortem brain sample by different quan-
tification tools. There are 30 overlapped candidate genes
from 722 and 511 candidate genes by Wu et al. and
Huang et al. The 30 candidate genes may represent the
co-expressed genetic interactions by different quantifica-
tion measurement. The cross-talk of genetic interaction
by these co-expressed genes and reached candidate
genes may address the key network in disease pathology.
The 30 candidate genes contains 4 PPIs which was for-
mulated by 7 candidate genes including SLC25A5,
PRKACA, APEX1, NUDT3, RPS14, FGF1 and S100A13.
There are 7 candidate genes formulated 94 PPIs which
contain 73 candidate genes from both Wu et al. and
Figure 2 Venn diagram of overlapped candidate genes in NGS
BA22 brain samples and SZGene. This diagram shows the
heterogeneous variation of result with different quantitative tools.
Candidate genes from Wu et al.(2012) were selected by TopHat
+Cufflinks, whereas SCZCGs were selected by Bowtie 1+RSEM. There
are 30 candidate genes appeared in both Wu et al. and SCZCGs.
Only 2 candidate genes existed simultaneously in SZGene and NGS
BA22 brain samples.
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Huang et al. If queried 1233 candidate genes from Wu
et al. and Huang et al., there are 41 candidate genes in
top 63 candidate genes (count ≥ 3), the overlapped rate
is 3.3%. However, there are 12 genes found in top 63
candidate genes from 73 candidate genes in cross-talk
genetic interaction of Wu et al. and Huang et al. The
overlapped rate improved up to 16.4% with 5 times
increase. The accuracy of candidate genes evaluated
from different quantification tools could be improved by
crosstalk analysis of overlapped genes in genetic
networks.
The genes reported by both Wu et al. and SZGene are
involved in biological functions such as mitochondrial
ATP synthase complex, platelet degranulation, beta-
amyloid binding protein, DNA binding, transcription
activity, calcium binding protein and cell cycle. How-
ever, the biological functions of genes reported by both
Huang et al. and SZGene are calcium ion binding, cell
cycle, platelet degranulation, MAPK activity, DNA bind-
ing, glycogen debranching enzyme activity, ATP binding,
fatty acid metabolic process, cytoskeleton structure,
transcription activity and ubiquitin ligase complex. The
genes reported in multiple datasets have similar biologi-
cal function, and results in higher confidence of poten-
tial candidate genes for schizophrenia. It also indicates
that the molecular network and biological processes are
likely to be disturbed in schizophrenia patients[49]. Dif-
ferential expressed gene exposure to atypical antipsycho-
tic quetiapine are cell cycle-associated in the frontal
cortex[50].
Query-Query PPI (QQPPI) network analysis of over- and
under- expressed candidate genes in schizophrenia
A total of 511 candidate genes in SCZCGs including 160
over-expressed and 351 under-expressed genes are used
to construct a QQPPI network of schizophrenia[51].
The network consists of 156 genes with 184 PPIs as illu-
strated in Figure 3. The zoomed areas show the linked
over-expressed subsets. PRKACA, TP53, SP1 and
STAT3 have the highest degree centrality, in which
STAT3, TP53 and PRKACA are under-expressed genes,
while SP1 is an over-expressed gene. The SEC24C gene
is associated with neurotransmitter transporters[52],
while FGF1 and S100 family are related to schizophrenia
[48,53].
The maximal subnetwork of 14 over-expressed genes
includes MCM10, CDKN2A, SIVA1, TBL1X, SIN3A,
SP1, MEF2C, MEIS2, TPM3, S100A2, PRKCZ, PARD3,
PLCB3 and CAMK2B. In this subnetwork, SP1 has been
reported to be abnormally expressed in schizophrenia
[54]. SP1-dependent abnormal expression results in dys-
function of the mitochondrial complex I subunit[55].
SIN3A and TPM3 have also been reported to be asso-
ciated with schizophrenia[56,57]. MEF2C is associated
with adaptive selective pressure and the potential role in
learning and memory[58]. The maximal subnetwork of
over-expressed genes was searched against CORUM, in
which the PLCB3-PARD3-PARD6A complex[59] was
found. The complex induces transcriptional activation in
intracellular Ca2+ and the Wnt signaling pathway. The
Wnt pathway is crucial for synaptic plasticity and its
defect may contribute to the pathogenesis of schizophre-
nia[60,61]. It is implicated that PLCB3-PARD3-PARD6A
complex may be associated with the pathology for schi-
zophrenia. Other schizophrenia-associated complexes in
SCZCGs are also searched against CORUM which are
listed in Table 2. The complexes involve spliceosome,
mitochondrial ribosome and other proteins which
mediated regulation transcriptions, second-messenger-
mediated signaling, ribosome biogenesis and protein
transport.
Schizophrenic candidate pathway analysis with FDR
adjustment
The pathway enrichment analysis was performed on
SCZCGs to select candidate pathways in schizophrenia
using multiple pathway databases including PID, Cell-
Map, Reactome and HumanCyc. 624 enrichment path-
ways are derived from SCZCGs in which 112 pathways
were selected by their significance in p-value and FDR
using the Benjamini-Hochberg procedure (Additional
file 4). Alteration of DARPP-32 expression level in STG
of postmortem brain was found in schizophrenia[62],
which highlight the importance of pathological change
of dopamine and glutamate systems in schizophrenia. In
order to explore the interactions and biological func-
tions among those enrichment pathways, the enrichment
pathways from PID were analyzed for crosstalk activity
(Figure 4). The interacting pathways involving biological
Figure 3 BA22 NGS differential expression query genes in
QQPPI network. The QQPPI network formulated by SCZCGs
illustrates the comprehensive genetic interactions for schizophrenia.
Two subnetworks with continuous linkage of over-expressed
candidate genes might reveal the potential pathways and biological
function for pathophysiology of schizophrenia.
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function may also contribute to the pathology of schizo-
phrenia which includes transcription activity, signaling
pathway, cancer-related pathway, tumor suppression,
coagulation, insulin secretion, cell cycle, cell differentia-
tion and apoptosis.
Pathways reported to be associated with pathogenesis of
schizophrenia include apoptosis[63], immune system
[64], TNF signaling pathways[65], hemostasis[66], p53
pathway[67], BARD1 signaling pathway[68], ceramide
signaling pathway[69], ErbB2 signaling pathway[70] and
androgen receptor pathway[71] and HDAC signaling
pathway[72,73].
Differential gene expression and mediator network
clustering analysis
Although the SCZCGs represent the significant differen-
tially expressed genes of schizophrenia, they may not be
sufficient to present the whole picture of schizophrenia.
Many mediator genes may be involved in the genetic
interactions without being detected as they are not
usually in abundance. In order to further analyze the
disease mechanism for schizophrenia, the SCZMN was
constructed using the genetic interactions of SCZCGs
and mediator genes.
The SCZMN that consisted of 5361 PPIs may poten-
tially represent the most comprehensive schizophrenia-
associated genetic network. The SCZMN was decom-
posed into clusters for analysis using the MCL algo-
rithm. The MCL algorithm is an efficient graph
clustering algorithm which helps classify SCZMN into
differential expression groups of optimal subnetworks.
The algorithm partitions SCZMN into clusters that are
measured by edge weight of the corresponding nodes.
Each cluster was calculated according to their p-value
with corresponding expressed genes and mediators. The
involved over- and under-expressed genes in MCL clus-
ters with p-value are listed in Additional file 5.
In cluster 1, one of the highly ranked complexes searched
against CORUM is the USP1-UAF1 complex which was
reported as a schizophrenic candidate complex, and its
inhibitor, Pimozide, is one of the antipsychotics with the
neuroleptic property of treating schizophrenic patients[74].
It has been postulated that the USP1-UAF1 complex is
associated with pathogenesis for schizophrenia. The SIRT1
gene is another candidate gene in cluster 1, which was
associated with schizophrenia in a haplotype-wise analysis
and may play an important role in the pathophysiology of
schizophrenia in the Japanese population[75].
Cluster 39 contains under-expressed genes such as
DRD2, KIF21A and PTPRU. It also contains GRIA2, SNPs
within GRIA2 has been report to influence the response to
antipsychotic treatment in schizophrenia[76]. However,
the new antipsychotic such as paliperidone has changed
the serum level of coagulation factors VIII and IX in rats
[77]. One of the mediator genes of cluster 39, NCS-1 gene
can mediate desensitization of D2 dopamine receptors[78].
Table 2 SCZCGs associated with CORUM complexes and its GO characterization.




Spliceosome LSM4*, CDK12*, PPIL3^, THOC5*, EFTUD2 * RNA splicing and binding
55S ribosome, mitochondria MRPL52*, MRPL15*, MRPL48*, MRPL43* Protein biosynthesis, mitochondria matrix
39S ribosomal subunit,
mitochondria
MRPL52*, MRPL15*, MRPL48*, MRPL43* Protein biosynthesis, mitochondria matrix
VEGF transcriptional complex APEX1*, CITED1*, STAT3* Regulation of transcription




SLC25A5*, RPS14^, TCOF1* Ribosome biogenesis
AP3-BLOC1 complex AP3S2*, SNAP1N*, DTNBP1* Protein targeting and transport
Figure 4 The crosstalk of PID candidate pathways from over-
and under-expressed candidate genes for schizophrenia. The
enrichment pathways with over- and under-expressed candidate
genes indicated the pathway involving biological function including
transcription activity, signaling pathway, cancer-related pathway,
tumor suppression, coagulation, insulin secretion, cell cycle, cell
differentiation and apoptosis.
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The NCS-1 protein expression was decreased in the pre-
frontal cortex and in T lymphocytes and NK cells of schi-
zophrenic patients[79]. Besides, SLC6A3 polymorphisms
are associated with schizophrenia[80].
The complexes searched against CORUM revealed
that the 2AR-mGluR2 complex involved in altered corti-
cal process might be potential target for treatment of
schizophrenia due to interaction with HTR2A (2AR)
and metabotropic glutamate receptors (mGluR)[81]. It is
implicated that there are potential complexes in cluster
39 which may be involved in the pathogenesis of schizo-
phrenia. The functional annotation of MCL in SCZCGs,
searched against DAVID with cluster number over 30,
was shown in Table 3.
Mitochondrial dysfunction in schizophrenic candidate
genes
Dopamine modulates mitochondrial function through
inhibition of respiratory complex I activity by abnormal
interaction between dopamine and mitochondrial func-
tion[82]. The genetic interaction for mitochondria func-
tion and schizophrenia were illustrated by DRD2 linked
to NDUFS7 through protein-protein interactions of
FLNA and ARRB2[83,84]. Treatment with psychotropics
might ultimately enhance energy metabolism and reduce
the damage of oxidative stress[85]. SNX3 and MRPL15
are over-expressed candidate genes which interact with
mitochondrial functions. BARD1, RBMS1, PRKAB1,
UBE2L3, SCO2, PIN4, MRPL43, BAG6, NDUFB11,
CAPN1, STAT3, MPST, TCOF1 and SEC24C are all
under-expressed genes which interact with the Respira-
tory chain complex I in mitochondria (Figure 5).
Wu et al. listed 4 candidate genes (NDUFB4,
NDUFS4, NDUFA5 and NDUFS7) located in the inner
membrane of mitochondria, however, in this study 15
candidate genes are found (except NDUFB11) not
located in the mitochondria but interact and regulate
mitochondria functions. They may turn off or disturb
the biological function of mitochondria and energy
metabolism in schizophrenia.
Wu et al. found 17 major candidate genes associated
with the Mitochondrial Complex I Subunits that contains
44 mitochondria genes according to CORUM. Since the
mitochondria is responsible for vital biological processes
such as energy metabolism, calcium buffering and apop-
tosis, it indicates the importance of mitochondrial dys-
function in the manifestation of schizophrenia[6].
Schizophrenic differential gene expression in coagulation
The candidate genes for schizophrenia are compared
with datasets of different brain samples and literature
databases. To investigate the relationship between
Table 3 Functional annotation of MCL in SCZCGs by DAVID.
Cluster No.(cluster genes >30)
(SCZCGs/cluster genes)


































QUERY Cluster: 9 (3/31) LMO3^,MCM10^,SDCBP2* DNA replication
Cell cycle
ATP binding
QUERY Cluster: 10 (3/31) FN1*,IGLL5*,ST14* Hemostasis
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hemostasis and schizophrenia, the hemostatic PPI net-
work of differentially expressed candidate genes was
analyzed and illustrated in Figure 6. Huang et al.
reported 12 differentially expressed candidate genes in
the hemostasis pathway of the Reactome database which
consists of F8, FN1, SIN3A, NOS1, OLR1, PLAU,
PRKACA, PRKCZ, RAD51B, TP53, CALU and PICK1.
Similarly, Wu et al. reported 18 candidate genes in the
hemostasis pathway of the Reactome database which
consists of HMG20B, GP1BB, HRAS, HIST2H3A,
KCNMB1, ATP2B2, PPIA, PRKACA, PRKCG, KLC2,
SOD1, TBXA2R, TF, TUBA4A, MAFK, CALM2,
CALM3 and CD63.
Figure 6 illustrates gene interactions from different
schizophrenic candidate gene datasets, such as under-
expressed genes (DRD2, F8, FN1 and GIPC1) and over-
expressed candidate genes (CALR, CDKN1A, FGL1 and
UBC). There are many coagulation related mediator
genes in the schizophrenia-coagulation gene interaction
network such as F2, F3, F5, F7, F8, F9, F10, F11, F13A1,
F13B, FGA, FGB, FGG, FN1, GGCX, PLAT, PROS1,
SERPINA5, SERPINB6, SERPINB8 and SERPINF2. Two
of them (FN1 and F8) are under-expressed coagulation
genes in SCZCGs.
Many genes in the network have been reported in pre-
vious studies. ALB, ANXA7 and CALR are candidate
genes in SZGene. The under-expressed candidate genes
reported by Huang et al.(2013) are F11, F7 and CLIC.
The over-expressed candidate gene (FGL1) and under-
expressed candidate gene (CDKN1A) have been
reported by Sellmann et al.(2013). HTR2A and DRD3
are listed as risk candidate genes for schizophrenia in
ClinVar. HTR2A, DRD2 and DRD3 interact with the
coagulation gene F3 through FLNA which causes a criti-
cal bottleneck and cascade into the following coagula-
tion pathways. It may be implicated as the potential




The mitochondrial dysfunction may decrease brain pH
by magnetic resonance spectroscopy studies in living
patients[86]. Mitochondrial dysfunction such as the
accumulation of mitochondrial DNA damage and reac-
tive oxygen species (ROS) production have underlined
the pathological mechanism for schizophrenia[87].
Reduced numbers of mitochondria in striatum and
impaired mitochondria activity in the caudate nucleus
have been associated with increased risk of schizophre-
nia[88]. Antioxidants seemed to improve mitochondrial
performance. Niacin, one of the antioxidant, could
Figure 5 Genetic interactions for mitochondria dysfunction in
schizophrenic candidate genes. This figure illustrates the genetic
interaction network for mitochondrial associated genes and
schizophrenic candidate genes. The blue nodes located inside the
mitochondria denoted the under-expressed schizophrenic candidate
genes from Wu et al. Red and green nodes located outside from
mitochondria(except NDUFB11) represent over and under-expressed
candidate genes from this study. NDUFB11 was found in both
candidate genes from Wu et al. and this study. It indicates the
mitochondrial associated under-expressed candidate genes
manifested by mitochondrial dysfunction may contribute to the
susceptibility of negative symptom for schizophrenia.
Figure 6 Genetic network of coagulation function in
schizophrenia. The genetic network of hemostatic process
implicates the interactions between antipsychotic target genes such
as DRD2/3 and HTR2A and coagulation factor genes such as F7, F3,
and F10 through bridging of actin-binding protein(FLNA) which
implicates the bottleneck of this network to cascade the following
coagulation function with different candidate genes in
schizophrenia.
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improve the manifestation of schizophrenic symptoms.
NNMT, HCAR2 and QPRT are targets of nicotinic
receptors. Reduced NNMT mRNA level was noted in
post-mortem schizophrenic patients[89]. QPRT-
involved kynurenine pathway of cortical metabolism is
impaired in schizophrenia[90]. HCAR2 protein was sig-
nificantly decreased in schizophrenic group[91].
Decreased niacin receptor responses were manifested
in schizophrenia, and niacinamide is neuroprotective
which is potentially associated with the pathogenesis of
schizophrenia[92]. Treatment of niacin could improve
mutism in a patient with mitochondrial encephalopa-
thy and schizophrenia[93].
The potential regulatory pathway for hemostasis in
schizophrenia
It has been postulated that hemostatic markers of throm-
bogenesis are increased in acute psychotic patients.
Increased serum level of coagulation factor VIII and plate-
lets are reported in acute psychotic patients[94]. Throm-
boembolism in schizophrenic patients may result from
pathological change of schizophrenic candidate genes or
the administration of antipsychotic. The reason for home-
ostasis in schizophrenia ascertains that increased risk of
thrombogenesis in schizophrenic patients with antipsycho-
tics treatment has been reported. Second-generation anti-
psychotics such as Olanzapine, Risperidone and Clozapine
are associated with increased dose-dependent risk of
venous thromboembolism[95,96] which result from par-
tially inhibition of platelet aggression in schizophrenic
patients[97].
Regulatory pathways of involving under-expressed
candidate genes in schizophrenia
In this study, three candidate pathways are associated
with under-expressed candidate genes (Figure 7). LKB1
signaling pathway interacts with under-expressed genes
PRKAB1 and STRADA. PRKAB1 is associated with poly-
morphisms in AMP-activated protein kinase (AMPK)
and antipsychotic-induced weight gain[98]. In addition,
PRKACA contained cluster which involved neurotrans-
mission related functions may be relevant to the patho-
physiology of schizophrenia[16]. It also appears in the
candidate genes for schizophrenia in SZGene. It is impli-
cated that AKT/GSK3 pathway may contribute to the
development of schizophrenia[99]. Glycogen synthase
kinase 3-b (GSK3b) has a vital role in many intracellular
signaling pathways which involved in gene transcription,
cytoskeletal reorganization, energy metabolism, cell cycle
regulation, and apoptosis. GSK3b activity also has been
associated with schizophrenia[100]. GSK3b polymorph-
isms might be involved in Parkinson’s disorder and schi-
zophrenia risk[101]. The research findings suggest that
LKB1 activity induced transcriptional functions including
phosporylation of GSK3b and APC binding to microtu-
bules which mediates the microtubule stabilization in the
leading process tip[102]. LKB1 signaling pathway is cru-
cial for neuronal migration in the developing neocortex
and dysfunction of LKB1 signaling pathway may play a
crucial role in neuronal migration and the development
of schizophrenia.
BARD1 signaling pathway contains three under-
expressed genes, BARD1, PCNA and UBE2L3, in which
UBE2L3 polymorphism is associated with schizophrenia
[103], and polymorphism study reveals that BARD1 is
risk allele for schizophrenia[68]. It indicates that BARD1
signaling pathway dysfunction may represent a novel
susceptibility pathway for schizophrenia.
The Aurora A signaling pathway interacts with under-
expressed genes including TP53, PRKACA, ARHGEF7
and PPP2R5D. TP53 is considered as a candidate suscept-
ibility gene for schizophrenia which may play a role in the
pathogenesis of schizophrenia[104]. PPP2R5D is in co-
expression network in Wnt pathway of schizophrenia tis-
sue sample[98]. It is implicated that inhibition of the Aur-
ora A signaling pathway may be a novel susceptibility
pathway for schizophrenia.
Hedgehog signaling pathway and schizophrenia
The Hedgehog signaling pathway is one of the signifi-
cant signaling pathways involving schizophrenic candi-
date genes such as SIN3A, CSNK1G3, PRKACA, and
SPOP. The crosstalk of PID candidate pathway for schi-
zophrenia between hedgehog signaling pathway and
other cancer-related pathways such as LKB1 signaling
events, Aurora signaling pathway, ErbB2/ErbB3 signaling
pathway and TNF alpha/NFkB signaling pathway. Cross-
talk between hedgehog and other signaling pathways
Figure 7 Under-expressed enrichment pathway network for
schizophrenia. These proteins involved in three signaling pathways
including BARD1 signaling events, LKB1 signaling events and Aurora
A signaling reveals the under-expressed enrichment pathways
which may implicate key roles in pathogenesis of schizophrenia.
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such as PI3K/AKT pathway is critical in the develop-
ment of embryonic cell and cancer therapies[105].
Genetic variation in MED12 which has been implicated
in neural development is associated with schizophrenia,
and its mutations link with deregulated GLI3-dependent
sonic hedgehog signaling pathway[106]. Antipsychotics
such as Clozapine, Chlorpromazine and Haloperidol reg-
ulate hedgehog signaling pathway through DHCR7 mod-
ulation[107]. Hedgehog signaling pathway may represent
a pathogenesis of schizophrenia.
Rho signaling pathway is also responsible for schizo-
phrenia[15]. ARHGAP18 is associated with schizophre-
nia[108]. ARHG (also known as RHOG) family genes
are associated with schizophrenia[109] which encodes a
member of the Rho family of small GTPases. Rho pro-
teins promote reorganization of the actin cytoskeleton
and regulate cell shape, attachment, and motility. In this
study, there are schizophrenic candidate gene including
RHOG family genes such as under-expressed genes,
ARHGEF38, ARHGAP1, ARHGAP36 and ARHGEF7;
and over-expressed genes, ARHGEF1.
Coagulation network in schizophrenia
The use of second-generation antipsychotics (such as
Clozapine, Risperidone and Olanzapine) is associated
with an increased risk of venous thromboembolism
[95,96]. The biological mechanisms responsible for the
possible thrombosis reaction are not quite clear. In schi-
zophrenia-coagulation network, the SCZCGs including
F8, FN1 and FGL1 are differential expressed candidate
genes which are associated with coagulation function.
They may account for the variant gene expression by not
only schizophrenia itself, but also by antipsychotic
administration.
Some hypotheses have been suggested such as drug-
induced sedation, obesity, enhanced platelet aggregation,
increased levels of antiphospholipid antibodies, hyperpro-
lactinemia, hyperhomocysteinemia and smoking which
result in increased activity in the coagulation system
[12-14]. However, evidence of venous thromboembolic
events in schizophrenia may be induced by psychosis
itself rather than by antipsychotic administration[8].
Moreover, chronic anticoagulation therapy (such as war-
farin) is associated with remission of psychotic symp-
toms, which suggest that imbalance of plasminogen
activator levels in the brain may affect the stabilization of
psychotic symptoms[10].
In this study, SCZCGs are discovered and associated
with coagulation function, which may result from the
variant gene expression by not only schizophrenia itself,
but also by antipsychotic administration. This network
also implicated the genetic interactions between hemos-
tasis pathway and antipsychotic associated genes (DRD2,
DRD3 and HTR2A) which implicated the potential
explanation of increased coagulation activity in antipsy-
chotic treatment.
The relationship between dopamine, serotonin and
coagulation function
The well-understood pathophysiology of schizophrenia is
cytoskeleton deficit and cell cycle. Cytoskeleton-associated
proteins play crucial roles not only in cell regulation and
migration but also in cell proliferation. A cytoskeleton-
associated gene mutations in the filamin A (FLNA) cause
periventricular heterotopia (PH), cell cycle prolongation,
compromised neural progenitor proliferation, and reduced
brain size[110]. However, FLNA is one of the novel schi-
zophrenia candidate genes[20] which was involved in the
glutamate receptor signaling subnetwork, and might result
in brain structure change such as enlargement of the cere-
broventricular system, reduced size in cortical region, and
abnormal laminar organization with differential genetic
changes including abnormal expression of multiple pro-
teins that are involved in cellular functionality such as
neuron migration, cell proliferation, axonal outgrowth,
and apoptosis[111].
HTR2A interact with DRD3 through GNAI1, DRD2
and DRD3 interact with FLNA cascade the subsequently
coagulation associated genes such as F3, F7, F10 and
UBC which provides antipsychotic biological mechanism
of dopamine D2/D3 receptor subtypes that involved
downstream signaling pathway through the cytoskeleton
of actin filaments[112,113].
Signaling pathway of coagulation function in
schizophrenia
The risk for cardiovascular mortality among those with
schizophrenia is increased twofold as compared with
patients without schizophrenia[114]. There is increasing
evidence of association between venous thromboembo-
lism and antipsychotic administration[115], especially
second-generation antipsychotics including Clozapine,
Olanzapine and Risperidone[116,117]. The pathogenesis
of elevated risk of thrombosis for schizophrenic patients
are not clear, which result from poor life style, enhanced
platelet aggregation, sedative medication, obesity, and
lack of movement[118]. It is implicated that the risk of
VTE in schizophrenia may result from disease itself
instead of the antipsychotic medication[13].
Figure 8 illustrated the possible mechanism proposed
for the explanation of molecular changes in coagulation
pathway in schizophrenia. The stress exposure activated
the modulating mechanism of DRD2/3 through cytoske-
letal protein interaction of FLNA in neuronal cell
[112,119,120], which induce F3 gene expression to the
release of tissue factor[121]. The gene-stress model
revealed the stress exposure magnitude are associated
with DRD2 genotype[122], which induced the expression
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of TF gene by increased SP1 transcriptional activity[123],
which may trigger release of tissue factor to activate the
extrinsic coagulation pathway containing FVII/FVIIa
induced platelet aggregation and initiate signaling cas-
cade for the extrinsic blood coagulation[124] which cas-
cade the following hemostatic reaction in neuron cell.
Moreover, oxidative stress contributes to activate the
over-expressed gene of tissue factor in the clotting sys-
tem[125].
Conclusions
The big data analysis of NGS by high-throughput tech-
nology brought new insights to the global view of com-
plex diseases, which helped to explain the
interrelationships among potential pathways and protein
complexes, and to discover biological function from the
corresponding cortical region. The next generation data
of RNA sequence revealed more detailed transcriptional
alteration in schizophrenia.
In this study, the comparison and integration of differ-
ential expression candidate genes are analyzed from differ-
ent literatures to explore the relationships between the
mitochondrial dysfunction and hemostatic pathways in
schizophrenia and control samples. By the integration of
transcriptome alteration in NGS BA22 brain tissue and
analysis of differential expression candidate genes, the
SCZCGs of schizophrenia provide a major approach for
the discovery of potential complexes and pathways, which
investigation of potential schizophrenic pathology with
mitochondrial and coagulation pathways. It is implicated
that the hypofunction of mitochondria may contribute to
the pathogenesis of negative symptoms of schizophrenia
such as hypoactivity, loss of energy, weakness and social
withdraw, which restoration of mitochondria function or
energy metabolism might be a potential strategy for
improvement of the negative symptoms of schizophrenia.
The thromboembolism in schizophrenia revealed the
potential alteration of hemostatic pathways which may
result from the interaction of antipsychotic target genes
with coagulation factor genes. The critical role of
HTR2A and DRD2/3 interact with the tissue factor (F3)
through FLNA which potentiates a bottleneck in coagu-
lation network. It may illustrate the potential mechan-
ism of thromboembolism in schizophrenia.
In analysis of SCZMN, the clusters screened by the
gene function classification tool may reveal the candi-
date complexes or pathways to discover the potential
pathogenesis for schizophrenia. It helped to explain the
interrelationships among potential pathways and protein
complexes, and to discover biological function from the
corresponding cortical region. The potential hemostatic
process and mitochondria-related complexes could be
implicated for the disease mechanism of schizophrenia.
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